Tesamorelin vs ipamorelin compared: GHRH analog versus ghrelin-receptor agonist, half-life, approval status, and how far apart the human evidence actually sits.
Tesamorelin and ipamorelin are both filed under "growth-hormone secretagogues," and that shared label hides how different they are. They engage different receptors and sit at opposite ends of the evidence spectrum: one is an approved pharmaceutical with pooled phase 3 data behind it, the other a selectivity-optimized research pentapeptide whose only sizeable human trial missed its endpoint.
Tesamorelin is a stabilized analog of human growth-hormone-releasing hormone (GHRH). It is the full 44-amino-acid GRF sequence with a trans-3-hexenoic acid group attached at the N-terminus — a modification that blocks the rapid degradation which limits native GHRH and the shorter GRF(1-29) fragment. It acts at the GHRH receptor on pituitary somatotrophs, amplifying the endogenous GH pulse rather than replacing it.
Ipamorelin works on the other arm of GH regulation. It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and an agonist at the growth-hormone secretagogue receptor GHSR-1a — the ghrelin receptor. Raun and colleagues described it in 1998 as the first selective GH secretagogue: in their preclinical work it released GH without meaningfully raising ACTH or cortisol, even at doses far above the ED₅₀ for GH release. That selectivity is ipamorelin's defining characteristic and the reason it is still discussed decades later, given that earlier GHRPs carried more off-target endocrine activity.
Because the two act at separate receptors, their signals are complementary rather than redundant — which is why GHRH analogs and ghrelin-receptor agonists are frequently studied in combination in the preclinical literature.
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH (GRF) analog | Ghrelin-receptor (GHSR-1a) agonist |
| Structure | 44-aa GRF + N-terminal trans-3-hexenoic acid | Pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Receptor | GHRH receptor, pituitary somatotrophs | GHSR-1a |
| Half-life | Very short — roughly ten to thirty minutes subcutaneously, varying by formulation and population per the FDA label | ~2 hours terminal, from human PK/PD modelling |
| Approval status | FDA-approved 2010 (Egrifta) for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy | No approved indication in any major jurisdiction |
| Best human evidence | Two pooled phase 3 RCTs, 412 patients, 26 weeks | Phase 2 proof-of-concept in postoperative ileus, ~114 randomized |
| Headline result | Visceral adipose tissue −15.2% vs +5.0% on placebo; triglycerides fell | Did not separate from placebo on GI-recovery endpoints; well tolerated |
| Selectivity note | Preserves pulsatile GH release; raises IGF-1 and IGFBP-3 | GH release without meaningful ACTH/cortisol elevation in preclinical work |
This is the honest asymmetry between the two. Tesamorelin's pivotal programme — the phase 3 work pooled and reported by Falutz and colleagues — randomized 412 patients with HIV-associated excess abdominal fat to 2 mg daily subcutaneously or placebo for 26 weeks, with an extension phase for safety. CT-measured visceral adipose tissue fell 15.2% on tesamorelin and rose 5.0% on placebo, with a concurrent drop in triglycerides. The effect was largely confined to the visceral compartment; subcutaneous fat moved comparatively little. That is a real, replicated, regulator-reviewed result in a defined population.
Ipamorelin has nothing comparable. Its largest controlled human study is Beck et al. (2014), a randomized, double-blind, placebo-controlled proof-of-concept trial of intravenous ipamorelin for postoperative ileus in bowel-resection patients. It was negative: ipamorelin did not shorten time to first meal intake and showed no significant difference from placebo on the key efficacy analyses. It was, however, well tolerated over up to seven days of twice-daily dosing — a tolerability signal, not efficacy. Essentially all of the body-composition discussion around ipamorelin rests on preclinical work and the mechanistic plausibility of GHSR-1a agonism.
Tesamorelin's label documents hypersensitivity reactions, edema-related events including arthralgia and peripheral edema, hyperglycemia, and injection-site reactions — the last at roughly 25% versus 14% on placebo across the trials. Because it raises IGF-1, glucose-tolerance shifts and IGF-1 monitoring are explicit label considerations. Any GH-axis stimulant carries this same theoretical concern.
Ipamorelin's tolerability record is thinner simply because far fewer people have received it under controlled conditions. Absence of reported adverse events in a ~114-patient trial is not the same as an established safety profile, and it says nothing about chronic administration.
If the research question concerns visceral adipose tissue specifically, tesamorelin is the compound with the actual dataset — that is the entire argument for it. Its daily-injection cadence follows from its very short half-life; the stabilizing modification extends resistance to degradation, not circulating time.
If the question is about GHSR-1a signalling, GH-pulse amplification through the ghrelin arm, or secretagogue selectivity, ipamorelin is the more specific tool and a cleaner one than older GHRPs. It is not a weaker tesamorelin; it is a different experiment, and reading results across the two arms is the most common error in this comparison.
For deeper background on each, see the Tesamorelin research overview and the Ipamorelin research overview, or the broader growth-hormone secretagogue category guide. Product pages: Tesamorelin and Ipamorelin.
Is tesamorelin stronger than ipamorelin? "Stronger" is the wrong axis. They act at different receptors, so their GH-release curves are not directly comparable, and no head-to-head human trial exists. What separates them is evidence depth, not potency: tesamorelin has pooled phase 3 data in a specific population, ipamorelin does not.
Are tesamorelin and sermorelin the same thing? No. Sermorelin is the GRF(1-29) fragment. Tesamorelin is the full 44-amino-acid GRF sequence carrying an N-terminal trans-3-hexenoic acid modification that resists degradation. Both are GHRH-receptor agonists, but they are structurally distinct molecules with different stability.
Why are GHRH analogs and ghrelin-receptor agonists studied together? Because they engage separate regulatory arms of the same axis. GHRH-receptor stimulation and GHSR-1a agonism are complementary signals in preclinical models, which is why combination designs appear in the literature. That mechanistic rationale is not the same as demonstrated combination efficacy in humans.
Does ipamorelin raise cortisol or prolactin? The 1998 Raun work reported GH release without ACTH or cortisol elevation significantly different from GHRH stimulation alone, even well above the ED₅₀ — the finding behind its "selective" designation. That is preclinical characterization, and human data on this point remain limited.
Why is ipamorelin's half-life longer if tesamorelin lasts longer in practice? Circulating half-life and duration of biological effect are different measures. Tesamorelin clears in minutes but triggers a downstream GH and IGF-1 response that persists far beyond the parent compound. Comparing half-lives across mechanistically different molecules tells you little on its own — see the dosing math guide for how these figures translate in practice.